Tag: Canine Atopic Dermatitis Market

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Canine Atopic Dermatitis Market Growth Potential: How Will Market Size Shift Through 2030?

The canine atopic dermatitis market size has experienced rapid expansion in recent years. It is anticipated to grow from $2.76 billion in 2025 to $3.05 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to an increasing occurrence of allergic skin conditions in dogs, greater awareness among pet owners and veterinarians, a prior lack of specific therapeutic options, the utilization of glucocorticoids and antihistamines as initial treatments, and the growth of veterinary dermatology services.

The canine atopic dermatitis market is set for significant expansion in the upcoming years. It is projected to climb to $4.5 billion in 2030, growing at a compound annual growth rate (CAGR) of 10.2%. The anticipated growth during this period is driven by factors such as the creation of novel biologics and monoclonal antibodies (mAbs), increasing financial commitment to precision medicine for companion animals, the expanding use of topical and systemic immunotherapies, the proliferation of online and retail distribution networks, and an emphasis on preventive and supportive care, including nutraceuticals. Prominent trends expected in the forecast timeframe involve the increasing application of monoclonal antibodies (mAbs) for focused treatments, the rising adoption of allergen-specific immunotherapy (ASIT) among dogs, a surge in the demand for medicated shampoos and topical applications, the wider availability of nutraceuticals and probiotics to bolster skin barrier health, and a dedicated focus on breed-specific treatment strategies for canine atopic dermatitis.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=25717&type=smp&name=Canine%20Atopic%20Dermatitis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Canine Atopic Dermatitis Market Industry Drivers: What’s Behind The Revenue Growth?

The canine atopic dermatitis market is anticipated to expand due to the growing incidence of skin allergies in dogs. These canine skin allergies involve atypical immune reactions to irritants like pollen, food, or flea bites, manifesting as itching, redness, and irritation of the skin. The uptick in canine skin allergy cases is partly linked to greater exposure to environmental contaminants and allergens, which can provoke intensified immune responses and skin irritation. Managing skin allergies in dogs through canine atopic dermatitis treatment aids in alleviating inflammation and itching, while also warding off secondary infections, thus enhancing their well-being and dermatological condition. For example, in January 2024, data from the National Institutes of Health (NIH), a US-based government entity, indicated that 7,915 dog owners (28.7%) stated their dogs had experienced skin-related problems. The frequency of reported skin problems showed a steady increase with age, commencing at 7% for puppies and climbing to 37% for older dogs. Consequently, the rising instances of skin allergies in dogs are fueling the expansion of the canine atopic dermatitis market.

Canine Atopic Dermatitis Market Segment Landscape: Which Areas Lead Development?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

#Canine Atopic Dermatitis Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies in the canine atopic dermatitis market are prioritizing the attainment of regulatory approvals to expand the availability and adoption of their treatments across global markets. These official permissions, granted by government health authorities, allow companies to commercialize and sell their medical products after rigorously demonstrating their safety, efficacy, and quality. For example, in September 2024, Elanco Animal Health Inc., a US-based pharmaceutical company specializing in animal health, obtained US FDA approval for Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis. Zenrelia’s approval signifies a considerable advancement in managing itchy dogs experiencing chronic, acute, or seasonal itch and inflammation, all provided in a single, once-daily tablet from the start. It operates by targeting the origin of the itch, obstructing the pathways responsible for allergic itch to break the itch-scratch cycle. Zenrelia offers noticeable improvement from the initial dose and lowers the likelihood of rebound itch, a frequent problem observed in many dogs treated with competing JAK inhibitors.

Canine Atopic Dermatitis Market Company Landscape And Competitive Strategy

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., Royal Canin SAS, Ceva Santé Animale S.A., Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Nextmune AB, OKAVA Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Toray Industries Inc., LEO Pharma A/S, PetIQ Inc., Hester Biosciences Limited, Ourofino Saude Animal, Swedencare AB, Orion Corporation, Norbrook Laboratories Ltd., AB Science SA.

View The Full Canine Atopic Dermatitis Market Report:

https://thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Canine Atopic Dermatitis Market Largest Region: Which Geography Holds The Biggest Share?

North America was the largest region in the canine atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Allergy Conjunctivitis Market Expected To Change Between 2026 And 2030?

The market for canine atopic dermatitis has seen rapid expansion in recent years. It will grow from $2.76 billion in 2025 to $3.05 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth observed in the past can be attributed to an increasing prevalence of allergic skin conditions in dogs, heightened awareness among pet owners and veterinarians, a previous scarcity of targeted treatments, the adoption of glucocorticoids and antihistamines as primary therapies, and the expansion of veterinary dermatology services.

The market for canine atopic dermatitis is projected to experience substantial expansion in the coming years. This market is forecast to reach $4.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this growth during the forecast period include the advancement of new biologics and monoclonal antibodies (mAbs), greater investment in precision medicine for companion animals, increased use of topical and systemic immunotherapies, the expansion of online and retail distribution channels, and an emphasis on preventive and supportive care, such as nutraceuticals. Key trends expected within this period involve the rising application of monoclonal antibodies (mAbs) for targeted therapies, the expanding uptake of allergen-specific immunotherapy (ASIT) in canines, a greater need for medicated shampoos and topical solutions, the broadening use of nutraceuticals and probiotics to support skin barrier health, and a concentration on treatment strategies tailored to specific dog breeds for canine atopic dermatitis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

Which Economic Or Industry Drivers Are Impacting The Allergy Conjunctivitis Market?

A projected increase in instances of canine skin allergies is anticipated to drive the expansion of the canine atopic dermatitis market. These allergies represent unusual immune reactions in dogs to various allergens, including pollen, specific foods, or flea bites, leading to symptoms such as itching, skin redness, and irritation. The escalation in canine skin allergy occurrences is partly linked to greater exposure to environmental contaminants and allergens, which can provoke intensified immune reactions and irritate the skin. Treatments for canine atopic dermatitis assist in controlling these skin allergies by mitigating inflammation and itchiness, and by averting subsequent infections, ultimately enhancing the dogs’ comfort and dermatological well-being. For example, data from January 2024 by the National Institutes of Health (NIH), a US government agency, indicated that 7,915 dog owners, representing 28.7%, reported their dogs previously experienced skin conditions. The frequency of these reported skin problems showed a consistent increase with age, from 7% in puppies to 37% in older dogs. Consequently, the growing number of canine skin allergy cases is fostering the expansion of the canine atopic dermatitis market. The increasing trend of pet ownership is projected to stimulate the growth of the canine atopic dermatitis market in the future. Pet ownership involves maintaining and looking after a domesticated creature, like a dog, cat, or bird, as a household companion. This rise is attributed to the growing humanization of pets, where animals are regarded as family members, thereby boosting the demand for their companionship and the emotional support they provide. Addressing canine atopic dermatitis offers advantages for pets by alleviating persistent itching and inflammation, fostering better skin health, and improving their general comfort and standard of living. For example, the American Pet Products Association (APPA), a US trade group for pet product manufacturers and suppliers, reported in April 2025 that 94 million US households, or 71%, will own a pet in 2025, an increase from 86.9 million households (66%) in 2023-2024. Thus, the expanding rate of pet ownership is propelling the growth within the canine atopic dermatitis market.

How Is The Allergy Conjunctivitis Market Structured Across Different Segments?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Which Trends Are Shaping The Future Of The Canine Atopic Dermatitis Market?

Companies operating in the canine atopic dermatitis market are primarily focused on securing regulatory approvals to expand the accessibility and adoption of their treatments across international markets. Regulatory approvals are the official permissions granted by government health authorities, allowing companies to sell their medical products after demonstrating their safety, effectiveness, and quality through rigorous testing. For example, in September 2024, Elanco Animal Health Inc., an animal health pharmaceutical company based in the US, obtained US FDA approval for Zenrelia, an oral JAK inhibitor administered once daily for dogs with allergic and atopic dermatitis. Zenrelia’s approval represents a significant step forward in managing dogs afflicted with chronic, acute, or seasonal itch and inflammation, offering a comprehensive solution in a single, daily tablet from the start. It functions by targeting the core source of the itch, blocking the specific pathways responsible for allergic itch to disrupt the itch-scratch cycle. Zenrelia delivers clear improvement from the first dose and reduces the likelihood of rebound itch, a frequent problem in many dogs treated with competing JAK inhibitors.

Which Major Players Dominate The Allergy Conjunctivitis Market?

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., Royal Canin SAS, Ceva Santé Animale S.A., Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Nextmune AB, OKAVA Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Toray Industries Inc., LEO Pharma A/S, PetIQ Inc., Hester Biosciences Limited, Ourofino Saude Animal, Swedencare AB, Orion Corporation, Norbrook Laboratories Ltd., AB Science SA.

Read the full canine atopic dermatitis market report here:

https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

What Are The Top-Performing Regions Within The Allergy Conjunctivitis Market?

North America was the largest region in the canine atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Allergy Conjunctivitis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

Browse Through More Reports Similar to the Global Canine Atopic Dermatitis Market 2026, By The Business Research Company

Dermatitis Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Dermatology Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Dog Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the artificial intelligence (ai) tele-oncology radiation dose scheduler market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Canine Atopic Dermatitis Market reach by 2030 starting from 2026 levels?

The canine atopic dermatitis market size has seen rapid growth in recent years. This market is expected to increase from $2.76 billion in 2025 to $3.05 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. The historical growth can be attributed to factors including the rising prevalence of allergic skin conditions in dogs, increased awareness among pet owners and veterinarians, a past limited availability of targeted therapies, the adoption of glucocorticoids and antihistamines as primary treatments, and the expansion of veterinary dermatology services.

The market for canine atopic dermatitis is projected to experience swift expansion over the coming years, reaching a valuation of $4.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. This anticipated growth during the forecast timeframe is attributable to several factors, including the emergence of new biologics and monoclonal antibodies (mAbs), augmented investments in precision medicine tailored for pets, a greater uptake of both topical and systemic immunotherapies, the expansion of online and retail distribution networks, and an increased emphasis on preventive and supportive treatments, such as nutraceuticals. Key trends anticipated during this period encompass the expanded application of monoclonal antibodies (mAbs) for targeted interventions, a rise in the acceptance of allergen-specific immunotherapy (ASIT) among dogs, a heightened need for medicated shampoos and topical remedies, the widening availability of nutraceuticals and probiotics to bolster skin barrier function, and a concentrated effort on developing breed-specific therapeutic strategies for canine atopic dermatitis.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

Which Drivers Are Influencing Long-Term Growth In The Canine Atopic Dermatitis Market?

The rising prevalence of skin allergies in dogs is projected to drive the expansion of the Canine Atopic Dermatitis market moving forward. Skin allergies in canines denote unusual immune reactions to substances like pollen, certain foods, or flea bites, leading to signs such as itching, reddening, and skin irritation. The increase in these cases among dogs is partly due to heightened exposure to environmental contaminants and allergens, which can activate strong immune responses and skin discomfort. Treatment for canine atopic dermatitis assists in handling these skin allergies by decreasing inflammation and pruritus, and by preventing subsequent infections, thus enhancing their overall comfort and dermatological health. For example, in January 2024, data from the National Institutes of Health (NIH), a US-based government agency, showed that 7,915 dog owners (28.7%) indicated their dogs had previously experienced skin-related issues. The occurrence of reported skin problems steadily climbed with age, commencing at 7% in puppies and reaching 37% in older dogs. Consequently, the growing incidence of skin allergies in dogs is propelling the growth of the Canine Atopic Dermatitis market.

Which Segments Are Driving Activity In The Canine Atopic Dermatitis Market?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Which Trends Are Influencing The Development Of The Canine Atopic Dermatitis Market?

Leading firms within the canine atopic dermatitis market are prioritizing securing official authorizations to broaden the reach and acceptance of their treatments globally. These approvals represent formal consent issued by governmental health agencies, enabling companies to distribute and sell their medical offerings once their safety, effectiveness, and quality have been substantiated through stringent evaluations. As an illustration, in September 2024, Elanco Animal Health Inc., a pharmaceutical company based in the US and focused on animal health, obtained US FDA clearance for Zenrelia, an oral JAK inhibitor administered once-daily for canines suffering from allergic and atopic dermatitis. Zenrelia’s endorsement represents a notable stride in addressing the needs of dogs experiencing chronic, acute, or seasonal itching and inflammation, providing a solution in a single, once-daily tablet from the very start. Its mechanism involves targeting the root cause of the itch, obstructing the specific pathways linked to allergic itching to break the recurring itch-scratch pattern. Zenrelia offers noticeable improvement right from the first dose and lessens the probability of rebound itch, a frequent concern observed in numerous dogs receiving treatment with rival JAK inhibitors.

Which Leading Companies Dominate The Canine Atopic Dermatitis Market Share?

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., Royal Canin SAS, Ceva Santé Animale S.A., Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Nextmune AB, OKAVA Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Toray Industries Inc., LEO Pharma A/S, PetIQ Inc., Hester Biosciences Limited, Ourofino Saude Animal, Swedencare AB, Orion Corporation, Norbrook Laboratories Ltd., AB Science SA.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

How Does The Canine Atopic Dermatitis Market Perform Across Major Global Regions?

North America was the largest region in the canine atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Canine Atopic Dermatitis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

Browse Through More Reports Similar to the Global Canine Atopic Dermatitis Market 2026, By The Business Research Company

Dermatitis Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Dermatology Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Dog Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Canine Atopic Dermatitis Market Covering 2025–2034?

The canine atopic dermatitis market size has seen significant rapid expansion in recent years. It is anticipated to expand from $2.49 billion in 2024 to $2.76 billion in 2025, progressing at a compound annual growth rate (CAGR) of 10.6%. The expansion observed historically is a result of factors such as increasing pet ownership, enhanced consciousness regarding pet well-being, the rising incidence of allergic conditions in canines, growing spending on veterinary healthcare, and the expanded accessibility of pet insurance.

The market size for canine atopic dermatitis is predicted to experience substantial expansion over the next few years. It is expected to climb to $4.09 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated growth can be attributed to factors such as the increasing incorporation of telemedicine in veterinary care, the rising demand for personalized treatments for pets, increased investment in veterinary research and development, the expanding trend of pet humanization, and the growing application of artificial intelligence in veterinary diagnostics. Significant trends during the forecast period involve the advancement of monoclonal antibody treatments, the utilization of artificial intelligence in veterinary diagnostics, the integration of telemedicine for dermatology, the adoption of wearable devices for tracking symptoms, sophisticated allergen-specific immunotherapy, and mobile applications for overseeing treatment.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Canine Atopic Dermatitis Industry?

An increase in canine skin allergy cases is anticipated to drive expansion in the canine atopic dermatitis market going forward. These allergies manifest as unusual immune reactions to substances like pollen, certain foods, or flea bites, leading to symptoms such as itching, redness, and irritated skin. The growing incidence of these conditions in dogs is partly linked to more frequent exposure to environmental contaminants and allergens, which can provoke stronger immune responses and skin irritation. Treatments for canine atopic dermatitis are effective in managing these skin issues by alleviating inflammation and itching, preventing subsequent infections, and consequently enhancing the dogs’ comfort and dermatological well-being. As an illustration, data from January 2024, provided by the US government agency National Institutes of Health (NIH), indicated that 7,915 dog owners (28.7%) confirmed their dogs had prior skin-related ailments. The frequency of reported skin problems showed a steady increase with age, beginning at 7% in puppies and escalating to 37% in older dogs. Consequently, the rising number of skin allergy cases in dogs is propelling the growth of the canine atopic dermatitis market. An anticipated increase in pet ownership is set to boost the expansion of the canine atopic dermatitis market going forward. Pet ownership describes the practice of keeping and looking after a domesticated creature, like a dog, cat, bird, or another companion animal, within a home environment. This rise can be attributed to the growing humanization of pets, where animals are considered family members, thereby increasing the demand for companionship and emotional support. Addressing canine atopic dermatitis offers advantages for pets by easing chronic itching and inflammation, improving their skin condition, and elevating their general comfort and life quality. For example, in April 2025, figures from the American Pet Products Association (APPA), a US trade group for pet product manufacturers and suppliers, indicated that 94 million US households (71%) will own a pet in 2025, up from 86.9 million US households (66%) owning a pet in 2023-2024. Consequently, the increase in pet ownership is stimulating growth in the canine atopic dermatitis market.

What Are The Major Segments Identified In The Canine Atopic Dermatitis Market?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

What Trends Are Redefining The Canine Atopic Dermatitis Market Dynamics?

Leading businesses within the canine atopic dermatitis market are concentrating on securing regulatory authorizations to broaden the reach and acceptance of their treatments internationally. These approvals denote formal consents issued by governmental health bodies, enabling firms to commercialize and distribute their medical offerings once their safety, effectiveness, and standard have been verified via stringent evaluations. A notable illustration occurred in September 2024, when Elanco Animal Health Inc., an American pharmaceutical firm focused on animal well-being, acquired US FDA clearance for Zenrelia, an oral JAK inhibitor administered once daily to canines suffering from allergic and atopic dermatitis. Zenrelia’s endorsement represents a considerable stride forward in alleviating discomfort for dogs experiencing chronic, acute, or seasonal itching and inflammation, delivered conveniently in one daily tablet from the start of treatment. Its mechanism involves targeting the root cause of the itch, thereby obstructing the routes that trigger allergic itching and effectively breaking the itch-scratch loop. Furthermore, Zenrelia provides noticeable enhancement right from the first dose and diminishes the chance of a rebound itch, a frequent problem observed in numerous dogs receiving alternative JAK inhibitor treatments.

Which Leading Companies Dominate The Canine Atopic Dermatitis Market Share?

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., IDEXX Laboratories Inc., Royal Canin SAS, Ceva Santé Animale S.A., Boragen, Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Antech Diagnostics Inc., Vetoquinol S.A., Heska Corporation, Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Bioceltix S.A., Nextmune AB, OKAVA Pharmaceuticals Inc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

What Regional Growth Trends Are Shaping The Canine Atopic Dermatitis Market Outlook?

North America was the largest region in the canine atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Canine Atopic Dermatitis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

Browse Through More Reports Similar to the Global Canine Atopic Dermatitis Market 2025, By The Business Research Company

Atopic Dermatitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Dermatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Canine Atopic Dermatitis Market Expected To Grow In Terms Of Size?

The market size for canine atopic dermatitis has seen swift expansion in the past few years. There is an anticipated growth from $2.49 billion in 2024 to $2.76 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.6%. This surge during the historic phase can be credited to factors such as the escalating number of pet owners, heightened awareness regarding pet health, a rising incidence of allergy-related conditions in dogs, an increase in spending on veterinary healthcare, and a wider availability of pet insurance.

The market size for canine atopic dermatitis is predicted to witness quick expansion in the following years. It is projected to escalate to $4.09 billion by 2029, with a compound annual growth rate (CAGR) of 10.3%. This projected growth during the forecast period could be attributed to factors like the rising preference for telemedicine in veterinary care, an increase in demand for tailored pet solutions, advancements in veterinary research and development, the growing trend of treating pets like a part of the family, and increased incorporation of artificial intelligence into veterinary diagnostics. Predicted trends for the forecast period encompass the evolution of monoclonal antibody treatments, the implementation of artificial intelligence in veterinary diagnostics, the integration of telemedicine for dermatology, the usage of wearable gadgets for symptom tracking, advanced allergen-specific immunotherapy, and mobile applications for monitoring treatment.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

What Are The Primary Factors Supporting The Canine Atopic Dermatitis Market Expansion?

An escalation in the incidence of skin allergies among dogs is anticipated to stimulate the expansion of the canine atopic dermatitis market. Skin allergies in dogs are unusual immunological reactions to allergens such as pollen, food or bites from fleas, leading to symptoms like itching, inflammation, and skin irritation. The increment in skin allergy cases in dogs is partially due to increased exposure to environmental pollutants and allergens, producing amplified immune responses and skin irritation. Therapies for canine atopic dermatitis aid in the management of skin allergies in dogs by decreasing inflammation and itching and preventing secondary infections, thereby enhancing their comfort and skin health. As per data from the National Institutes of Health (NIH), a US governmental agency, in January 2024, a total of 7,915 dog owners, which accounts for 28.7%, indicated that their dogs had a history of skin conditions. The rate of reported skin problems rose consistently with age, beginning at 7% in puppies and growing to 37% in senior dogs. Hence, the surge in skin allergy cases in dogs is pushing the growth of the canine atopic dermatitis market. The increasing trend of pet ownership is expected to accelerate the canine atopic dermatitis market’s growth. Pet ownership implies owning and caring for a domestic animal, such as a dog, cat, bird, or another companion animal. The surge in pet ownership can be attributed to the growing trend of pets’ humanization, with animals being considered as family members, thus elevating the demand for companionship and emotional support. The treatment of canine atopic dermatitis is useful for pets as it alleviates chronic itching and inflammation, improves skin health, and enriches their overall comfort and quality of life. In April 2025, as per the American Pet Products Association (APPA), a trade association based in the US that supplies and produces pet products, 94 million US households (71%) owned a pet, an increase from 86.9 million US households (66%) owning a pet during 2023-2024. Therefore, the increment in pet ownership is propelling the growth of the canine atopic dermatitis market.

Which Segmentation Categories Are Highlighted In The Canine Atopic Dermatitis Market Analysis?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Which Market Trends Are Expected To Define The Future Of The Canine Atopic Dermatitis Market?

Leading corporations in the canine atopic dermatitis market are concentrating their efforts on securing regulatory approvals in order to increase the global reach and use of their therapies. Regulatory approvals are the official authorizations issued by government health departments that permit companies to distribute and sell their medical products after demonstrating their safety, efficacy, and quality through intensive testing. For example, Elanco Animal Health Inc., a pharmaceutical company from the US with a focus on animal health, was awarded US FDA approval for Zenrelia, a once-daily oral JAK inhibitor for dogs suffering from allergic and atopic dermatitis, in September 2024. The authorization of Zenrelia signifies a substantial progression in treating dogs with chronic, acute, or seasonal itch and inflammation, encapsulated in a single, once-daily tablet from the beginning. Zenrelia functions by identifying and inhibiting the itch source, disrupting the itch-scratch cycle. From the first dosage, Zenrelia provides noticeable improvements and lowers the chance of rebound itch, a frequent problem in numerous dogs treated with the rivaling JAK inhibitor.

Which Organizations Are At The Forefront Of The Canine Atopic Dermatitis Market?

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., IDEXX Laboratories Inc., Royal Canin SAS, Ceva Santé Animale S.A., Boragen, Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Antech Diagnostics Inc., Vetoquinol S.A., Heska Corporation, Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Bioceltix S.A., Nextmune AB, OKAVA Pharmaceuticals Inc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Canine Atopic Dermatitis Market?

North America was the largest region in the canine atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

Browse Through More Reports Similar to the Global Canine Atopic Dermatitis Market 2025, By The Business Research Company

Dog Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Canine Arthritis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/canine-arthritis-treatment-global-market-report

Allergy Conjunctivitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/allergy-conjunctivitis-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Canine Atopic Dermatitis Market Evolve in Terms of Growth and Size by 2029?

In the last few years, the market size for canine atopic dermatitis has seen rapid expansion. It is forecasted to rise from $2.49 billion in 2024 to $2.76 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. The growth observed during the historic period can be traced back to factors like a surge in pet ownership, heightened consciousness about pet health, an increase in the prevalence of allergic conditions in dogs, rising expenditure in veterinary healthcare, and enhanced availability of pet insurance.

The market size for canine atopic dermatitis is forecasted to witness substantial growth in the upcoming years, ballooning to $4.09 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 10.3%. This growth in the projected period can be assigned to the rise in the use of telemedicine in pet care, an increased demand for individualized pet therapies, surging investments in veterinary R&D, an increase in the trend of pet humanization, and a growing application of artificial intelligence in veterinary diagnostic procedures. Anticipated trends within this period include the advancement of monoclonal antibody therapies, integration of AI in veterinary diagnostics, the inclusion of telemedicine for dermatology, the use of wearable devices for tracking symptoms, sophisticated allergen-specific immunotherapies, and the emergence of mobile applications for treatment tracking.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

What factors are expected to fuel Canine Atopic Dermatitis market growth in the coming years?

An upward trend in skin allergy cases among dogs is predicted to stimulate the expansion of the canine atopic dermatitis market. Dog skin allergies are abnormal immunological reactions to allergens like pollen, food, or insect bites, leading to symptoms such as itchiness, erythema, and dermal irritation. This upsurge in dog skin allergies can be partially linked to heightened exposure to environmental pollutants and allergens, known to catalyse intense immunological reactions and dermal irritation. The treatment of atopic dermatitis in dogs helps handle dermal allergies in them by decreasing inflammation and itchiness and inhibiting secondary infections, thus improving their comfort and dermal health. For example, as per the National Institutes of Health (NIH), a US government body, in January 2024, a total of 7,915 dog parents (28.7%) confirmed their dogs suffered from dermal conditions. The reporting frequency of dermal problems spiked consistently with growing age, beginning at 7% in puppies to 37% in aged dogs. Consequently, the surge in dog skin allergy cases is pushing the growth of the canine atopic dermatitis market. Escalating pet ownership is also projected to boost the expansion of the canine atopic dermatitis market. Pet ownership implies owning and taking care of a domesticated animal like a dog, cat, bird, or a different companion animal, as a house member. The escalating pet ownership is due to the humanising of pets, animals being treated as family members, pushing demand for companionship and emotional support. Treating atopic dermatitis in dogs advantageously eases chronic itchiness and inflammation, betters dermal health, and amplifies their overall comfort and life quality. As per the American Pet Products Association (APPA), a US trade association that manufactures pet products, 94 million US households (71%) possess a pet in 2025, marking an increase from 86.9 million (66%) pet owning US households in 2023-2024. Consequently, escalating pet ownership is fuelling the expansion of the canine atopic dermatitis market.

What Are The Key Findings From The Segmentation Analysis Of The Canine Atopic Dermatitis Market?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Which Trends Are Expected To Shape The Future Of The Canine Atopic Dermatitis Market?

The dominant players in the canine atopic dermatitis market are working towards obtaining regulatory approvals to amplify their therapies’ global access and usage. These regulatory approvals are the official authorizations given by governmental health agencies. They permit companies to distribute and sell their medical products after these products have successfully passed comprehensive safety, efficacy, and quality tests. For example, Elanco Animal Health Inc., an American animal health pharmaceutical company, obtained US FDA approval for Zenrelia in September 2024. Zenrelia is a daily oral JAK inhibitor for dogs suffering from allergic and atopic dermatitis.Zenrelia’s approval marks a crucial step forward in the treatment of dogs with chronic, acute, or seasonal itch and inflammation with a single daily tablet. It operates by targeting and blocking the pathways responsible for allergic itches, effectively disrupting the itch-scratch cycle. Observational improvements can be seen from the first dose of Zenrelia, and it minimizes the risk of rebound itch, a common difficulty in numerous dogs treated with rival JAK inhibitors.

What Are The Most Active Companies In The Canine Atopic Dermatitis Market Today?

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., IDEXX Laboratories Inc., Royal Canin SAS, Ceva Santé Animale S.A., Boragen, Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Antech Diagnostics Inc., Vetoquinol S.A., Heska Corporation, Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Bioceltix S.A., Nextmune AB, OKAVA Pharmaceuticals Inc

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

Which Regional Markets Are Attracting The Most Investment In Canine Atopic Dermatitis?

North America was the largest region in the canine atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model